Cormedix (Cormedix) Debt-to-Equity

: 0.01 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

Cormedix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.15 Mil. Cormedix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.52 Mil. Cormedix's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $70.14 Mil. Cormedix's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cormedix's Debt-to-Equity or its related term are showing as below:

CRMD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 1.24
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Cormedix was 1.24. The lowest was 0.01. And the median was 0.02.

CRMD's Debt-to-Equity is ranked better than
99.91% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs CRMD: 0.01

Cormedix Debt-to-Equity Historical Data

The historical data trend for Cormedix's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.02

0.01

Cormedix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.02	0.01	0.02	0.01	0.01

Competitive Comparison

For the Biotechnology subindustry, Cormedix's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cormedix Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Cormedix's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cormedix's Debt-to-Equity falls into.

Cormedix Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cormedix's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.151	+	0.517)	/	70.142
	=	0.01

Cormedix's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.151	+	0.517)	/	70.142
	=	0.01

Cormedix (NAS:CRMD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cormedix Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cormedix's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cormedix (Cormedix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (NAS:CRMD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

19KA:Germany

Address

300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922

Website

https://www.cormedix.com

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.

Executives

Alan W Dunton	director	VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Erin Mistry	officer: Chief Commercial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Joseph Todisco	director, officer: Chief Executive Officer	400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Myron Kaplan	director	C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176
Paulo F Costa	director	MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Robert A Stewart	director	360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960
Janet Dillione	director	ONE WAYSIDE ROAD, BURLINGTON MA 01803
Matthew T David	officer: EVP, Chief Financial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Elizabeth Masson	officer: EVP, Head of Clinical Ops.	400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922
Thomas Nusbickel	officer: EVP, Chief Commercial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Gregory Scott Duncan	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Steven W Lefkowitz	director	SIX HARRISON STREET, NEW YORK NY 10013
Mehmood Khan	director	700 ANDERSON HILL ROAD, PURCHASE NY 10577
Armstrong Jr. John L.	officer: Exec VP of Tech Operations	C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Khoso Baluch	director, officer: Chief Executive Officer	1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921